Alpha Tau Medical Ltd

Alpha Tau Medical Ltd's next confirmed earnings release is scheduled for November 24, 2026.

As of June 30, 2026, Alpha Tau Medical Ltd has 90.18M shares outstanding.

As of June 30, 2026, Alpha Tau Medical Ltd maintains a current ratio of 11.09, meaning it holds 11.1x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Alpha Tau Medical Ltd posted a negative return on equity (ROE) of -141.68, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -75.51, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 112.00, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Alpha Tau Medical Ltd recorded 51.87M in income tax expense. The company reported a pretax loss of -27.39B and -27.44B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

Over the twelve months ended June 30, 2026, Alpha Tau Medical Ltd generated - - in revenue and converted that into -27.44B in net income, yielding earnings per share of -312.44. EBITDA reached -14.95B, while operating income came in at -14.95B.

As of June 30, 2026, Alpha Tau Medical Ltd holds 29.83B in cash and equivalents against 4.49B in total debt, resulting in a net debt position of -4.80B. Total book value stands at 13.06B, with working capital of 28.81B providing operational flexibility.